- Home
- PBFS vs ACIU Comparison
PBFS vs ACIU Comparison
Compare PBFS & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- ACIU
- Stock Information
- Founded
- PBFS 1889
- ACIU 2003
- Country
- PBFS United States
- ACIU Switzerland
- Employees
- PBFS N/A
- ACIU N/A
- Industry
- PBFS Banks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- ACIU Health Care
- Exchange
- PBFS Nasdaq
- ACIU Nasdaq
- Market Cap
- PBFS 309.6M
- ACIU 270.1M
- IPO Year
- PBFS N/A
- ACIU 2016
- Fundamental
- Price
- PBFS $11.75
- ACIU $2.65
- Analyst Decision
- PBFS
- ACIU Strong Buy
- Analyst Count
- PBFS 0
- ACIU 2
- Target Price
- PBFS N/A
- ACIU $12.00
- AVG Volume (30 Days)
- PBFS 20.9K
- ACIU 203.0K
- Earning Date
- PBFS 01-30-2025
- ACIU 03-13-2025
- Dividend Yield
- PBFS N/A
- ACIU N/A
- EPS Growth
- PBFS 6.93
- ACIU N/A
- EPS
- PBFS 0.73
- ACIU N/A
- Revenue
- PBFS $79,730,000.00
- ACIU $48,505,404.00
- Revenue This Year
- PBFS N/A
- ACIU $86.78
- Revenue Next Year
- PBFS N/A
- ACIU $118.22
- P/E Ratio
- PBFS $16.16
- ACIU N/A
- Revenue Growth
- PBFS 10.09
- ACIU 4097200.00
- 52 Week Low
- PBFS $8.76
- ACIU $2.25
- 52 Week High
- PBFS $12.05
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- PBFS 54.69
- ACIU 47.51
- Support Level
- PBFS $11.65
- ACIU $2.39
- Resistance Level
- PBFS $12.05
- ACIU $2.74
- Average True Range (ATR)
- PBFS 0.25
- ACIU 0.14
- MACD
- PBFS 0.02
- ACIU 0.01
- Stochastic Oscillator
- PBFS 62.96
- ACIU 56.52
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.